Video

Dr. Rana on Germline Genetic Testing in Advanced Prostate Cancer

Huma Q. Rana, MD, MPH, discusses germline genetic testing in men with advanced prostate cancer.

Huma Q. Rana, MD, MPH, clinical director, Cancer Genetics and Prevention, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses germline genetic testing in men with advanced prostate cancer.

Historically, genetic testing has been a mainstay for women with a personal or family history of breast cancer, says Rana. However, germline genetic testing should extend to men with advanced prostate cancer and men with potentially lethal prostate cancer.

However, there are challenges with implementing widespread genetic testing in this patient population, and reevaluation of testing methods is needed, explains Rana.

Logistical challenges regarding testing include additional appointments for patients with advanced disease, limited knowledge of germline genetic testing in the clinic, and a lack of genetics experts, concludes Rana.

Related Videos
Cedric Pobel, MD
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.